Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial

Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With GlioblastomaLARKSPUR, Calif.--(BUSINESS WIRE)--#GBMAGILE--Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and V...

Related Keywords

Zurich ,Züsz ,Switzerland ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Jim Mahoney ,Eliza Sullivan ,Biohaven Neuroinnovation ,Sam Martin ,Michael Weller ,Mike Beyer ,Jennifer Porcelli ,Tom Mikkelsen ,Howard Colman ,Rachel Rosenstein Sisson ,Linkedin ,Department Of Neurology ,University Hospital Zurich ,Global Coalition For Adaptive Research ,Twitter ,University Of Utah ,Sam Brown Inc ,Biohaven Pharmaceutical Holding Company Ltd ,Coalition For Adaptive Research ,National Brain Tumor Society ,Henry Ford Health ,Cure Brain Cancer Foundation ,Selection Committee ,Huntsman Cancer Institute ,Department Of Neurosurgery ,Precision Medicine Program Clinical Trials Office ,National Foundation For Cancer Research ,Asian Fund For Cancer Research ,Department Of Neurosurgery At Stanford University ,Vigeo Now Enrolling ,Registrational Phase ,Platform Trial ,Evaluate Interventions ,Patients With ,Global Coalition ,Adaptive Research ,Biohaven Pharmaceutical Holding Company ,Vigeo Therapeutics ,Michael Lim ,Stanford University ,Director Department ,Principal Investigators ,Medical Director ,Precision Medicine Program ,Clinical Trials Office ,Henry Ford ,Henry Ford Health Cancer ,Principal Investigator ,Vlad Coric ,Chief Executive Officer ,National Foundation ,Cancer Research ,Asian Fund ,Biohaven Pharmaceutical Ireland ,Investor Relations ,